Mode
Text Size
Log in / Sign up

Reactive nodular fibrous pseudotumor presents with distinct immunohistochemical profiles and no progression in patientsIdentifying Reactive Nodular Fibrous Pseudotumor to Avoid Overtreatment

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize reactive nodular fibrous pseudotumor as a benign entity with specific IHC markers to avoid overtreatment.

This case report and literature review characterizes the clinicopathological, immunohistochemical, and prognostic features of reactive nodular fibrous pseudotumor (RNFP). The analysis includes 4 cases from the primary cohort and a review of 40 additional cases. Histological findings across all cases showed low cellularity, abundant hyalinized collagen, and scattered bland spindle cells without cytologic atypia or mitoses.

Immunohistochemical profiles revealed that 100% of cases were vimentin positive, while 50% were SMA positive. CD34 showed focal expression in 25% of cases. Notably, 100% of cases were negative for STAT6, beta-catenin, S-100, and desmin. Molecular detection was uniformly negative across all cases. No recurrence or progression was observed during the follow-up period.

The authors note that the primary analysis is limited by a retrospective design and a small sample size of 4 patients. Despite these limitations, the review emphasizes the importance of recognizing RNFP's anatomical distribution, including rare pulmonary involvement. Clinicians should maintain awareness of these features to prevent misdiagnosis and potential overtreatment of benign lesions mimicking malignancy.

Doctors and researchers reviewed 44 cases of a condition called reactive nodular fibrous pseudotumor (RNFP). This is a type of growth that can look like a tumor but behaves differently. The study looked at the physical characteristics, cell types, and markers found in these tissues to help doctors identify them more accurately.

The findings showed that these growths have specific features, such as low cellularity and plenty of collagen. Testing showed they were positive for vimentin but negative for other markers like STAT6 or S-100. Importantly, no cases of recurrence or progression were found in the patients studied over a period of 6 to 60 months.

Because this condition can appear in various parts of the body, including the lungs, it is important for doctors to recognize its specific markers. This knowledge helps ensure that patients do not receive aggressive treatments intended for cancer when their condition is actually a reactive growth. However, because this report is based on a small sample size and a retrospective review, more research is needed to confirm these findings widely.

What this means for you:
Recognizing the specific markers of RNFP helps doctors avoid misdiagnosing it as a more serious tumor.

Common questions

What is a reactive nodular fibrous pseudotumor?

It is a type of growth that can look like a tumor but is actually a reactive tissue. The study found these cases had low cellularity and abundant collagen. Because they are not true tumors, identifying them correctly helps patients avoid treatments that are too aggressive for their condition.

How do doctors tell it apart from other conditions?

Doctors use specific tests called immunohistochemistry to look for markers. In this study, 100% of cases were positive for vimentin, while others like STAT6 and S-100 were negative. These specific results help doctors confirm the diagnosis and ensure the patient gets the right care.

Is this condition likely to come back?

In the cases studied, no recurrence or progression was observed over a follow-up period of 6 to 60 months. This suggests that the growth is stable, but you should always speak with your doctor about your specific diagnosis and long-term outlook.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
Reactive nodular fibrous pseudotumor (RNFP) is a rare benign fibrocollagenous lesion that often poses diagnostic challenges because of its nonspecific clinical and radiological features, particularly at unusual sites such as the lung. This study aimed to characterize the clinicopathological, immunohistochemical, and prognostic features of RNFP and summarize the literature. We retrospectively analyzed four pathologically confirmed RNFP cases, including a rare pulmonary case, and combined them with 40 reported cases (n = 44). RNFP occurred at multiple anatomical sites, most commonly in the abdomen, followed by the extremities and chest. The pulmonary lesion presented as a solitary nodule mimicking malignancy. Histologically, all lesions showed low cellularity, abundant hyalinized collagen, and scattered bland spindle cells without cytologic atypia or mitoses. Immunohistochemically, all cases were positive for vimentin; 50% expressed SMA and 25% showed focal CD34 expression, whereas STAT6, β-catenin, S-100, and desmin were consistently negative. All molecular detection results were uniformly negative. During follow-up (6–60 months), no recurrence or progression was observed. RNFP is a benign reactive lesion with characteristic histological and immunophenotypic features. Diagnosis relies on morphological assessment and immunohistochemical exclusion of mimics. Awareness of its anatomical distribution, including rare pulmonary involvement, is essential to avoid misdiagnosis and overtreatment.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.